2018 American Transplant Congress
Age Stratified Efficacy and Safety Outcomes of Induction Immunosuppression in Renal Transplantation
Purpose: Rejection and infection remain a leading concern for decreased graft survival after renal transplant (RT). Induction immunosuppression is associated with a decreased risk of…2018 American Transplant Congress
Clinical and Pathological Findings in Hepatitis C Positive Renal Transplant Recipients Following Alemtuzumab Induction
University of Maryland Medical Center, Baltimore.
BackgroundHistorically, renal transplant recipients (RTRs) with chronic hepatitis C (HCV) have worse long-term outcomes. Induction with alemtuzumab (ALM) in HCV positive RTRs has been postulated…2018 American Transplant Congress
Induction Type and Outcomes in HLA-DR Mismatch Kidney Transplantation
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
In kidney transplantation, donor-recipient HLA-DR mismatch is considered high immunologic risk portending inferior outcomes. We sought to explore the impact of induction type used on…2018 American Transplant Congress
Successful Transplantation in a Sensitized Patient Allergic to Commercially Available Antibody Induction Agents
Antibody induction in renal transplantation has increased to over 80%. Rabbit anti-thymocyte globulin (rATG) is the most commonly used agent. Hypotension, rash, dyspnea with rATG…2018 American Transplant Congress
Deceased Donor Urinary Biomarker Signature and the Effectiveness of Peritransplant Lymphocyte Depletion on Early Renal Allograft Function
Purpose: Delayed graft function (DGF) is associated with increased allogaft immunogenicity and decreased long-term survival. We hypothesized that high levels of donor urinary biomarkers for…2018 American Transplant Congress
Differences in Rejection and Clinical Outcomes in Obese versus Non-Obese Renal Transplant Recipients Receiving Basiliximab Induction Immunosuppression
Introduction: Basilixiab is a fixed-dose IL-2 receptor antagonist that is used for non-lymphodepleting induction therapy. The impact of obesity on basiliximab pharmacokinetics and pharmacodynamics is…2018 American Transplant Congress
Single Reduced Dose Thymoglobuline as Induction in Kidney Retransplant
Hospital do Rim, São Paulo, Brazil.
IntroductionKidney retransplant is a high risk procedure, without a consensus about the best induction imunnossupression strategy. Only a few studies have evaluated these growing proportion…2018 American Transplant Congress
Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort
Purpose: There is an elevated risk of acute rejection in HIV+ renal transplant recipients and continued evaluation of the most appropriate induction therapy remains. Use…2018 American Transplant Congress
A Meta-Analysis for Induction Therapy of Kidney Transplantation: Comparison of Antithymocyte Globulin and Interleukin 2 Receptor Antagonist
Objectives To compare the efficacy and safety of antithymocyte globulin (ATG) and interleukin 2 receptor antagonist (IL2Ra) in induction therapy of kidney transplantation.Method A literature…2018 American Transplant Congress
Improved Value with Individualized Antithymocyte Globulin Dosing Protocol in Renal Transplant
University of Virginia Healthsystem, Charlottesville, VA.
Medication costs represent one of the largest costs associated with transplantation. With growing pressure to reduce health care costs while maintaining excellent outcomes, this study…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 31
- Next Page »